Oncolytics Biotech Inc. Reports Highlights and Financial Result...( CALGARY March 6 / Oncolytics Biot...)

CALGARY, March 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today reported its financial results for the year ended December 31, 2007.

"2007 was our most productive year to date, marking a significant expansion of the Company's clinical trial program for REOLYSIN(R) with Phase II studies and combination drug therapy studies being expanded and initiated," said Dr. Brad Thompson, President and CEO of Oncolytics. "This activity was supported by further advances in our preclinical development program, manufacturing, and intellectual property."

Selected Highlights:

Clinical Trial Results Presented

--------------------------------

- Final results from our Phase I U.K. systemic administration trial, and

our U.S. Phase I systemic administration trial at ASCO;

- Positive interim results from our U.K. Phase Ia/Ib combination

REOLYSIN(R) and radiation trial;

Clinical Trial Progress

-----------------------

- Commenced patient enrolment in three combination REOLYSIN(R) and

chemotherapy trials in the U.K.;

- Commenced patient enrolment in a U.S. Phase II trial for patients with

various sarcomas that have metastasized to the lung;

- U.S. National Cancer Institute (NCI) filed a protocol with the U.S.

Food and Drug Administration (FDA) to conduct a Phase II melanoma

trial with REOLYSIN(R);

- Approval to begin a Phase I combination REOLYSIN(R) and

cyclophosphamide trial in the U.K.;

- In January 2008, the NCI filed a protocol with the U.S. FDA to conduct

a Phase I/II ovarian, peritoneal and fallopian tube cancer trial;

- In January 2008, met the criteria to expand to full enrolment of 52

patients in our U.S. Phase II sarcoma trial;

Manufacturing

-------------

- Completed scale up of our manufacturing process to
'/>"/>